CTRI/2016/07/007099招募中未知
Prospective open label study to assess the efficacy and safety of step-wise increase in dose of antihistamines in treating chronic spontaneous urticaria
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Patients >18 years of age
- •2.Patients fulfilling the definition of chronic spontaneous urticaria which is urticarial lesions occurring most days of the week (atleast 3 times a week) lasting for 6 weeks or more with no identifiable cause on history or examination.
排除标准
- •1. Patients less than 18 years of age,
- •2. Patients unwilling to participate in the study,
- •3. Patients with physical, contact, drug-induced urticaria and urticarial vasculitis
- •4. Pregnant or breast-feeding females
研究者
相似试验
进行中（未招募）
1 期
Study analyzing the efficacy and safety of low-dose oral immunotherapy in children with severe allergy to cow's milk treated with Omalizumab. ILO studySevere IgE-mediated cow's milk allergyMedDRA version: 20.0Level: HLGTClassification code: 10021505Term: Immunology and allergy investigations Class: 10022891MedDRA version: 20.0Level: PTClassification code: 10016946Term: Food allergy Class: 100000004870MedDRA version: 20.0Level: LLTClassification code: 10076438Term: Milk protein allergy Class: 10021428MedDRA version: 20.0Level: LLTClassification code: 10001745Term: Allergy to cow's milk Class: 10021428MedDRA version: 20.0Level: LLTClassification code: 10011240Term: Cow's milk allergy Class: 10021428MedDRA version: 20.0Level: PTClassification code: 10027633Term: Milk allergy Class: 100000004870CTIS2023-503958-12-00Hospital Infantil Universitario Nino Jesus20
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005597-38-DKF. Hoffmann-La Roche Ltd680
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 18.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005597-38-ESRoche Farma S.A. que representa en España a F. Hoffmann-La Roche Ltd600
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005597-38-IEF. Hoffmann-La Roche Ltd680
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005597-38-GBF. Hoffmann-La Roche Ltd750